Can Fite BioPharma Ltd (CANF)

[swanlinbar]

CANF Can-Fite ADRs Up; To Advance Piclidenoson into Phase II Covid-19 Trial in U.S.
7:53 am ET June 9, 2020 (Dow Jones) Print
By Michael Dabaie

Can-Fite BioPharma Ltd. ADRs were up 16%, to $2.37, premarket.

The biotechnology company said that in response to Can-Fite's Pre-Investigational New Drug filing with the U.S. Food and Drug Administration, the FDA has provided detailed comments regarding the prospective use of Piclidenoson to treat patients suffering from Covid-19.

The FDA's response allows Can-Fite to proceed to the next step of formally submitting an IND for Piclidenoson in this indication.

The planned Phase II trial will evaluate the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for Covid-19 infected patients with moderate-to-severe symptoms.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

June 09, 2020 07:53 ET (11:53 GMT)